Medulloblastoma in the Molecular Era

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Molecular Biology

Background:

• Medulloblastoma is the most frequent malignant pediatric brain tumor, contributing significantly to childhood cancer mortality.
• Recent advancements have identified four distinct molecular subgroups: wingless (WNT), sonic hedgehog, group 3, and group 4.
• Subgroup classification has refined risk stratification and influenced clinical trial design for medulloblastoma.

Purpose of the Study:

• To highlight the challenges in developing targeted therapies for medulloblastoma.
• To emphasize the need for personalized treatment strategies.
• To underscore the importance of considering tumor evolution in treatment selection.

Main Methods:

• Review of current understanding of medulloblastoma subgroups.
• Analysis of molecular heterogeneity within subgroups.
• Examination of treatment strategies at recurrence.

Main Results:

• Despite subgroup classification, significant molecular heterogeneity persists, complicating therapy prediction.
• Recurrent medulloblastoma often exhibits genetic divergence from primary tumors due to selective pressures.
• Tumor resampling at recurrence may be crucial for accurate patient selection for targeted therapies.

Conclusions:

• Current medulloblastoma subgroup classification, while advanced, is insufficient alone for predicting therapy response.
• The genetic landscape of medulloblastoma changes significantly from initial diagnosis to recurrence.
• Personalized therapy for medulloblastoma may necessitate repeated tumor sampling to guide treatment decisions.